secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001819790-24-000127
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M
---------------------------------------------------------------

- Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.
- Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.
- Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.
- Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.
- Cash and marketable securities of $317.0M as of September 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/0001819790-24-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/tars-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer